Condition
Overweight or Obese
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
12 shownWeight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical TrialNCT07514611 · 2026-04-18
RECRUITINGPistachio Snacking and Metabolic FlexibilityNCT07340125 · 2025-09-01
RECRUITINGA Study to Evaluate MWN109 Injection in Healthy SubjectsNCT06859853 · 2025-03-17
RECRUITINGPhase II Study of THDBH120 Injection in Overweight or Obese SubjectsNCT07036601 · 2025-01-06
RECRUITINGTirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)NCT07292519 · 2026-01-15
NOT_YET_RECRUITINGInnovative Functional Product for Overweight and ObesityNCT07044167 · 2025-09-07
COMPLETEDA Trial With EMP16 in Preparation for Late Phase StudiesNCT06993428 · 2025-05-20
NOT_YET_RECRUITINGA Study of BGM0504 in Healthy Participants and Participants With Impaired Renal FunctionNCT06929156 · 2025-05-06
COMPLETEDA Study of BGM0504 in Overweight or Obese ParticipantsNCT06920056 · 2025-03-24
COMPLETEDA Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 · 2024-11-21
COMPLETEDWeight Management in Mothers and Adult DaughtersNCT02787902 · 2018-08-01
COMPLETEDDose-Response to Exercise in Women Aged 45-75 Years (DREW)NCT00011193 · 2001-01-01
COMPLETEDCommon interventions
BGM0504DRUG2PlaceboDRUG2Alli® 60 mgDRUG1CommunicationBEHAVIORAL1Control without active polyphenolsDIETARY_SUPPLEMENT1dietary regulation and structured exercise trainingBEHAVIORAL1EMP16-02 120 mg orlistat/40 mg acarboseDRUG1EnicepatideDRUG1ExerciseBEHAVIORAL1MaltodextrinDIETARY_SUPPLEMENT1Metformin HydrochlorideDRUG1ParacetamolDRUG1PistachioOTHER1PlaceboOTHER1Placebo of THDBH120 injectionDRUG1Polyphenol-enriched functional productDIETARY_SUPPLEMENT1StandardBEHAVIORAL1Subcutaneous single and mutiple doseDRUG1Take Control CBT ModuleBEHAVIORAL1THDBH120 injectionDRUG1TirzepatideDRUG1Vi-Siblin® SDIETARY_SUPPLEMENT1WarfarinDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
BrightGene Bio-Medical Technology Co., Ltd.
2
Carmen Lucas Abellán
1
Carmot Therapeutics, Inc.
1
Empros Pharma AB
1
Guangdong Provincial People's Hospital
1
Pennington Biomedical Research Center
1
Shanghai Minwei Biotechnology Co., Ltd
1
South West Sydney Local Health District
1
Tonghua Dongbao Pharmaceutical Co.,Ltd
1
University of California, San Diego
1
University of South Carolina
1
Trial status mix
COMPLETED6
RECRUITING4
NOT_YET_RECRUITING2
Phase mix
NA4
PHASE24
PHASE13
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.